Effect of fractalkine-Fc delivery in experimental lung metastasis using DNA/704 nanospheres

P Richard-Fiardo1, B Cambien, E Pradelli

  • 1Archet I, Nice, France.

Cancer Gene Therapy
|August 27, 2011
PubMed

Insights

Aerosol delivery of a fractalkine (FKN)-encoding plasmid using copolymer 704 effectively inhibited lung metastases in mouse models. This non-invasive gene therapy shows promise for treating pulmonary tumors and stimulating antitumor immunity.

Area of Science:

  • Oncology
  • Gene Therapy
  • Nanotechnology

Background:

  • The lung is a common site for solid tumor metastasis.
  • Current systemic treatments for lung metastases have significant adverse effects.
  • Targeted, non-invasive drug/gene delivery to the lungs is needed.

Purpose of the Study:

  • To evaluate aerosol delivery of a fractalkine (FKN)-encoding plasmid formulated with tetrafunctional amphiphilic block copolymer 704.
  • To assess the efficacy of this approach in preclinical models of pulmonary metastases.

Main Methods:

  • Aerosolization of FKN-encoding plasmid formulated with copolymer 704.
  • Intratracheal administration in mouse models of colon carcinoma (CT-26) and osteosarcoma (K7M2) lung metastases.
  • Assessment of tumor growth inhibition following single and repeated administrations.

Main Results:

  • Repeated intratracheal administration of 704/FKN-Fc significantly inhibited the growth of experimental lung metastases in both CT-26 and K7M2 models.
  • Copolymer 704 demonstrated efficient and safe gene transfer to the lung via aerosolization.
  • FKN-Fc gene therapy showed potential for treating pulmonary metastases.

Conclusions:

  • Aerosolized FKN-Fc gene therapy using copolymer 704 is a promising strategy for managing lung metastases.
  • This approach offers a non-invasive, targeted method for gene delivery to the lungs.
  • FKN-Fc gene therapy may represent a novel immunotherapeutic approach for pulmonary tumors.

Related Concept Videos